Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 15/20 | 1.00 |
| ▸ | CA9 | Q16790 | 15/20 | 1.00 |
| ▸ | CA1 | P00915 | 14/20 | 1.00 |
| ▸ | CA12 | O43570 | 1/20 | 0.68 |
| ▸ | STS | P08842 | 5/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4665386 | 0.94 | CA2 (0.88) | CA2CA9CA1CA12STS | |
| SCHEMBL6801137 | 0.79 | CA1 (0.76) | CA2CA9CA1CA12STS | |
| SCHEMBL4976876 | 0.78 | CA2 (0.80) | CA2CA9CA1STS | |
| SCHEMBL9451266 | 0.76 | CA2 (0.76) | CA2CA9CA1CA12STS | |
| SCHEMBL2236572 | 0.76 | CA2 (1.00) | CA2CA9CA1CA12STS | |
| SCHEMBL9788649 | 0.76 | CA2 (0.61) | CA2CA9CA1CA12 | |
| SCHEMBL4609033 | 0.76 | CA2 (0.61) | CA2CA9CA1CA12 | |
| SCHEMBL14015362 | 0.76 | CA2 (0.61) | CA2CA9CA1CA12STS | |
| SCHEMBL9451347 | 0.76 | CA2 (1.00) | CA2CA9CA1CA12STS | |
| SCHEMBL9451471 | 0.76 | CA2 (1.00) | CA2CA9CA1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023242845-A1 | SULFAMATE BASED COVALENT LIGAND-DIRECTED RELEASE (CoLDR) COMPOUNDS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2023-12-21 | — | — | WO | disclosed |
| US-20230406837-A1 | SULFAMATE MODULATORS OF PIN1 ACTIVITY AND USES THEREOF | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2023-12-21 | — | — | US | disclosed |
| WO-2010017405-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230406837-A1 | SULFAMATE MODULATORS OF PIN1 ACTIVITY AND USES THEREOF | PIN1, PSTPIP2, PIN4 | CA2 1952/4885CA9 3791/4885CA1 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.